A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years
A Phase 3, Non-randomized, Single-arm, Open-label Study to Assess the Immunogenicity, Safety and Reactogenicity of Combined Reduced-antigen-content Diphtheria, Tetanus and Acellular Pertussis (dTpa) Vaccine, Administered as a Booster Dose in Healthy Japanese Adolescents Aged 11 Years to <13 Years
GlaxoSmithKline
85 participants
Jun 29, 2026
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to assess the immune response, reactogenicity and safety of a booster dose of dTpa vaccine 1 month after vaccination in healthy Japanese participants aged 11 to \<13 years.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Combined reduced antigen content diphtheria, tetanus and acellular pertussis (dTpa) vaccine administered at Day 1.
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07596173